Search clinical trials for: HX575 epoetin alfa (Sandoz)

Total 549 results

Sandoz
Hexal AG

Completed

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. (EPO-PASS)

Chronic Kidney Disease

Poland, Germany, Romania, Italy, Austria, Bulgaria, France, Macedonia, The Former Yugoslav Republic of, Russian Federation, Ukraine
Sandoz

Completed

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) (SENSE)

Chronic Kidney Disease

Russian Federation, Germany, Italy, Poland, Romania, Turkey, Ukraine
Sandoz

Terminated

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Anemia | Chronic Renal Insufficiency

Austria, Slovakia, Russian Federation, Romania, Poland, Czechia, France, Germany, India, Bulgaria
Sandoz

Withdrawn

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP) (SWEEP)

Anemia | Chronic Renal Insufficiency

Spain, Romania, Bulgaria, France, Germany
Sandoz

Completed

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa (ACCESS)

Anemia | Chronic Kidney Disease (CKD)

United States
Western Galilee Hospital-Nahariya

Unknown

Prevention of Contrast Induced Nephropathy by Erythropoietin

Diabetes | Chronic Kidney Insufficiency

Israel
Shahid Beheshti University of Medical Sciences
Pooyesh Darou

Completed

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

Myocardial Ischemic Reperfusion Injury

Iran, Islamic Republic of
University of Washington
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (PENUT)

Extreme Prematurity

United States
Sandoz
Hexal AG

Completed

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Anemia

Austria, Germany
Huiqing Sun
Göteborg University; Zhengzhou University

Enrolling by invitation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (EPO)

Developmental Disabilities
Zhengzhou University
Göteborg University; Zhengzhou Children's Hospital, China

Completed

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Premature Infants

China
Megalabs
Azidus Laboratories

Not yet recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients (ENCASE)

Anemia of Chronic Kidney Disease

Uruguay
Hospital de Clinicas de Porto Alegre
Oswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RS

Completed

Efficacy Study of Two Formulations of Erythropoietin

Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
M.D. Anderson Cancer Center

Completed

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Completed

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Anemia | Venous Thrombosis
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)

Anemia | Blood Transfusion | Orthopedic Procedures
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Anemia

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Anemia

United States, Puerto Rico
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Janssen-Cilag B.V.

Completed

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Neoplasms | Anemia

Netherlands
Janssen-Cilag B.V.

Completed

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Anemia | Blood Transfusion | Orthopedic Procedures
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
Janssen-Ortho Inc., Canada

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Anemia
Janssen Cilag S.A.S.

Terminated

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Anemia | Renal Failure, Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Amgen

Completed

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

Nephrology
Jonsson Comprehensive Cancer Center
Amgen

Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant Condition

United States
University of South Florida
Ortho Biotech, Inc.

Terminated

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (EPO)

Subarachnoid Hemorrhage

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Neoplasms | Cancer | Anemia

United States
GlaxoSmithKline
Quintiles, Inc.; ERT: Clinical Trial Technology Solutions; Q2 Solutions; HemoCue

Completed

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Anaemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Anemia | Surgery, Arthroscopy

3

Subscribe